20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
Rhea-AI Summary
20/20 BioLabs (Nasdaq: AIDX) entered a standstill agreement with Streeterville Capital effective July 16, 2026, covering its outstanding Series E Convertible Preferred Stock. For 120 days, Streeterville will not convert preferred shares to common stock unless AIDX trades at least 10% above the Nasdaq “Minimum Price.”
The arrangement is designed to temporarily limit potential dilution from preferred conversions while keeping all existing rights and obligations under the Series E Preferred Stock and related transaction documents otherwise unchanged. After the standstill ends or is terminated, conversions may resume under existing terms.
Positive
- 120-day cap on conversions below 10% above Nasdaq Minimum Price
- Standstill may reduce near-term dilution from Series E conversions
- Existing Series E and related documents remain in full force
Negative
- Standstill is temporary, lasting only 120 days from July 16, 2026
- Standstill ends immediately upon any breach or Event of Default
- Streeterville can fully resume conversions after standstill expiration
Market reaction after Series E standstill agreement: AIDX -6.76% in the Jul 23 session
In the Jul 23 session, AIDX declined 6.76%, reflecting a notable negative market reaction. Argus tracked a trough of -12.4% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 09 | Investor webinar | Positive | +1.1% | Focused on OneTest, Medicare strategy, and preliminary Q2 revenue growth expectations |
| Jun 22 | Webinar series launch | Positive | +2.8% | Announced recurring investor webinars and an inaugural July 1 session with management access |
| May 27 | Screening program selection | Positive | -4.9% | Selected for Vermont firefighter screening program expected to generate about $500,000 |
| May 22 | Testing contingency planning | Neutral | -18.7% | Prepared potential Ebola and Hantavirus PCR testing capacity without current authorization |
| May 20 | First-quarter earnings | Negative | -6.6% | Reported lower revenue, wider net loss, and improved liquidity after financing |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent reactions were mixed, with positive operational announcements producing both gains and declines; the Q1 earnings decline aligned with a negative reaction.
Key Terms
standstill agreement financial
convertible preferred stock financial
event of default regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution
GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into a standstill agreement (the “Agreement”) with Streeterville Capital, LLC (“Streeterville”) relating to the Company’s outstanding Series E Convertible Preferred Stock (the “Series E Preferred Stock”). The Agreement became effective on July 16, 2026.
Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common stock unless, on a given trading day, the common stock trades at a price at least
Upon expiration or termination of the Standstill, Streeterville may resume converting shares of the Series E Preferred Stock in accordance with the terms of the applicable transaction documents. Except as expressly provided in the Agreement, the Series E Preferred Stock and all related transaction documents remain in full force and effect.
Additional information regarding the Agreement will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected effects of the Agreement, including its anticipated impact on conversion activity, dilution and the trading market for the Company’s common stock, as well as the Company’s business strategy and prospects. These statements are often identified by words such as “believe,” “expect,” “intend,” “anticipate,” “plan,” “may,” “will,” “should” and similar expressions. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. There can be no assurance that the Agreement will have the intended effects, that the standstill will not terminate early, or that Streeterville will not convert shares of Series E Preferred Stock following the standstill period. Additional factors are described in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent reports. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
